Scholarlink

<p>The management of hyperphosphatemia is of critical significance given its high prevalence among hemodialysis (HD) patients and its strong association with worse outcomes. Clinical pharmacists can play a crucial role in medication management, but there is a critical shortage. Currently, there is rarely study evaluating how pharmacists in different roles can engage in medication management. The main aim of this study was to evaluate the impact of a pharmacist-led intervention using a hierarchical management model on hyperphosphatemia. A parallel, prospective, randomized, multicenter study was designed including patients at 9 recruited Dialysis Centers whose serum phosphate (sP) &gt; 4.5&#xa0;mg/dL with maintenance HD. Every Dialysis Center was allocated one pharmcist, primary management pharmacists (PMP) or senior management pharmacists (SMP), who was responsible for education. After 6-month study, the sP in the intervention group decreased from 6.36 ± 1.30&#xa0;mg/dL to 5.55 ± 1.34&#xa0;mg/dL, and was much lower than control group (6.02 ± 1.53&#xa0;mg/dL) (<i>p</i> &lt; 0.05). But the nutritional indicators, such as albumin and hemoglobin hadn’t been affected (<i>p</i> &gt; 0.05). Importantly, both PMPs and SMPs achieved clinically meaningful reductions in sP (<i>p</i> &lt; 0.05 for both within-group comparisons), with no statistically significant difference between the two groups (<i>p</i> = 0.11). These findings suggest that a hierarchical pharmacist management model—combining standardized education with targeted SMP support for high-risk patients—can enable PMPs to deliver care comparable to that of SMPs. This approach may help optimize limited pharmacy resources and expand access to high-quality medication management for hemodialysis patients with hyperphosphatemia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of a hierarchical pharmacist management model on reducing hyperphosphatemia in hemodialysis patients in China: a multicenter randomized study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月19日

查看全文
  • Xiaolan Ye,
  • Shujuan Wu,
  • Er-min Gu,
  • Xin Jiang,
  • Wentong Liu,
  • Tingting Ding,
  • Dongmin Xu,
  • Zhixing Pan,
  • Hengfei Tang,
  • Bo Hu,
  • Qiudi Tu,
  • Litong Wang,
  • Ping Huang

摘要

The management of hyperphosphatemia is of critical significance given its high prevalence among hemodialysis (HD) patients and its strong association with worse outcomes. Clinical pharmacists can play a crucial role in medication management, but there is a critical shortage. Currently, there is rarely study evaluating how pharmacists in different roles can engage in medication management. The main aim of this study was to evaluate the impact of a pharmacist-led intervention using a hierarchical management model on hyperphosphatemia. A parallel, prospective, randomized, multicenter study was designed including patients at 9 recruited Dialysis Centers whose serum phosphate (sP) > 4.5 mg/dL with maintenance HD. Every Dialysis Center was allocated one pharmcist, primary management pharmacists (PMP) or senior management pharmacists (SMP), who was responsible for education. After 6-month study, the sP in the intervention group decreased from 6.36 ± 1.30 mg/dL to 5.55 ± 1.34 mg/dL, and was much lower than control group (6.02 ± 1.53 mg/dL) (p < 0.05). But the nutritional indicators, such as albumin and hemoglobin hadn’t been affected (p > 0.05). Importantly, both PMPs and SMPs achieved clinically meaningful reductions in sP (p < 0.05 for both within-group comparisons), with no statistically significant difference between the two groups (p = 0.11). These findings suggest that a hierarchical pharmacist management model—combining standardized education with targeted SMP support for high-risk patients—can enable PMPs to deliver care comparable to that of SMPs. This approach may help optimize limited pharmacy resources and expand access to high-quality medication management for hemodialysis patients with hyperphosphatemia.